CTI Clinical Trial and Consulting Services   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Covington KY United States (1999)

Organization Overview

First Clinical Trial
2006
NCT00323037
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CTI Clinical Trial and Consulting | CTI Clinical Trial and Consulting Services

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acidosis (Phase 3)

Acidosis, Renal Tubular (Phase 3)

Adenocarcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Congenital Abnormalities (Phase 1)

Delayed Graft Function (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Heart Failure (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Kidney Diseases (Phase 2)

Liver Failure (Phase 2)

Mesothelioma (Phase 1)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Neoplasms (Phase 1)

Pneumonia (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 20